Therapy News and Research

RSS

NAMI publishes updated family guide for treating adolescents living with depression

The National Alliance on Mental Illness has published an updated and expanded edition of What Families Need to Know about Adolescent Depression, a guide for families who want to know about accurate diagnosis and effective treatment options for teenagers experiencing depression.

21 Dec 2010

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.

21 Dec 2010

Gilenya offers more benefits for MS therapy than previously realized

In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.

21 Dec 2010

Laser restoration therapy promotes hair regrowth in women

Many Women suffering from hair loss are turning to Advanced Hair Studios and discovering advanced laser therapy as a method along with other procedures to overcome thinning hair.

21 Dec 2010

Use of metaphors may help doctors to recruit low-income people for cancer clinical trials

The language that doctors use with low-income, rural patients can help determine whether these patients agree to participate in clinical trials testing new cancer treatments, a new study found.

21 Dec 2010

Writing habit 'is one of the top predictors of weight loss success'

The first step to reaching your ideal weight in the New Year may be as simple as writing it down.

21 Dec 2010

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

Touro University Worldwide introduces new online program in Marriage and Family Therapy

Dr. Bernard Luskin, CEO and Senior Provost of Touro University Worldwide recently announced its new online program in Marriage and Family Therapy with concentrations in pastoral counseling, coaching, mediation and dispute resolution.

21 Dec 2010

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Research led by St. Jude Children-s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer.

21 Dec 2010

Study examines treatment options for children diagnosed with ADHD

For doctors and parents to jointly decide how to attack pediatric conditions, such as attention-deficit/hyperactivity disorder (ADHD), practical barriers to recommended health treatments need to be overcome, according to a study by The Children's Hospital of Philadelphia. In considering their options, parents preferred their physicians to offer an unbiased presentation of all available treatments.

21 Dec 2010

Researchers develop new lung imaging technique that causes minimum tissue disruption

Fast-moving objects create blurry images in photography, and the same challenge exists when scientists observe cellular interactions within tissues constantly in motion, such as the breathing lung. In a recent UCSF-led study in mice, researchers developed a method to stabilize living lung tissue for imaging without disrupting the normal function of the organ.

21 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

'CART' treatment better than traditional cognitive therapy at altering hyperventilation and panic symptoms

A new treatment program teaches people who suffer from panic disorder how to reduce the terrorizing symptoms by normalizing their breathing.

21 Dec 2010

Treatment with acid-suppressive drugs associated with increased risk of pneumonia

Using acid suppressive medications, such as proton pump inhibitors and histamine2 receptor antagonists, may increase the risk of developing pneumonia, states an article in CMAJ (Canadian Medical Association Journal).

21 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.

20 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

U of A student wins annual master's thesis competition for research on light-sensitive drug for prostate cancer

The future of cancer treatment and a University of Alberta graduate student's personal career prospects are looking bright. Weiyang Liu beat competitors from 80 of the best university graduate schools in western North America with his master's thesis on the use of a light-sensitive drug to treat prostate cancer.

20 Dec 2010

Therapy News and Research

NAMI publishes updated family guide for treating adolescents living with depression

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Gilenya offers more benefits for MS therapy than previously realized

Laser restoration therapy promotes hair regrowth in women

Use of metaphors may help doctors to recruit low-income people for cancer clinical trials

Writing habit 'is one of the top predictors of weight loss success'

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Touro University Worldwide introduces new online program in Marriage and Family Therapy

New research sheds light on complex regulatory pathways for effective innate immune system

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Study examines treatment options for children diagnosed with ADHD

Researchers develop new lung imaging technique that causes minimum tissue disruption

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

'CART' treatment better than traditional cognitive therapy at altering hyperventilation and panic symptoms

Treatment with acid-suppressive drugs associated with increased risk of pneumonia

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Exciting progress made in MS research during 2010

U of A student wins annual master's thesis competition for research on light-sensitive drug for prostate cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News